Selected research
Market Outlook & Growth Opportunities
Global Peptide Synthesis CDMO Services Market Outlook and Growth Opportunities 2026
Market perspective
The global Peptide Synthesis CDMO Services market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Peptide Synthesis CDMO Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Peptide Synthesis CDMO Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Peptide Synthesis CDMO Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Peptide Synthesis CDMO Services market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Peptide Synthesis CDMO Services market include Bachem, CordenPharma, PolyPeptide, AmbioPharm, Genscript, Thermo Fisher, USV Peptides, Bio Basic and ScinoPharm, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Peptide Synthesis CDMO Services market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Peptide Synthesis CDMO Services and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Peptide Synthesis CDMO Services revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Peptide Synthesis CDMO Services market.
Peptide Synthesis CDMO Services Segment by Company
Bachem
CordenPharma
PolyPeptide
AmbioPharm
Genscript
Thermo Fisher
USV Peptides
Bio Basic
ScinoPharm
JPT
CBL
Piramal Pharma
CPC Scientific
Creative Peptides
Chinese Peptide Company
ChengDu ShengNuo Biotec
AppTec Co., Ltd.
GL Biochem
Peptide Synthesis CDMO Services Segment by Type
GMP Services
Non-GMP Services
Peptide Synthesis CDMO Services Segment by Application
Commercial
Scientific Research
Other
Peptide Synthesis CDMO Services Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Peptide Synthesis CDMO Services status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Peptide Synthesis CDMO Services key companies, revenue, market share, and recent developments.
3. To split the Peptide Synthesis CDMO Services breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Peptide Synthesis CDMO Services market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Peptide Synthesis CDMO Services significant trends, drivers, influence factors in global and regions.
6. To analyze Peptide Synthesis CDMO Services competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Synthesis CDMO Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Synthesis CDMO Services and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Synthesis CDMO Services.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peptide Synthesis CDMO Services industry.
Chapter 3: Detailed analysis of Peptide Synthesis CDMO Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Peptide Synthesis CDMO Services in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Peptide Synthesis CDMO Services in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Peptide Synthesis CDMO Services Industry Trends
Table 2. Peptide Synthesis CDMO Services Industry Drivers
Table 3. Peptide Synthesis CDMO Services Industry Opportunities and Challenges
Table 4. Peptide Synthesis CDMO Services Industry Restraints
Table 5. Global Peptide Synthesis CDMO Services Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Peptide Synthesis CDMO Services Revenue Share by Company (2021-2026)
Table 7. Global Peptide Synthesis CDMO Services Company Ranking, (2024-2026) & (US$ Million)
Table 8. Global Peptide Synthesis CDMO Services Key Company Manufacturing Base & Headquarters
Table 9. Global Peptide Synthesis CDMO Services Company, Product Type & Application
Table 10. Global Peptide Synthesis CDMO Services Company Establishment Date
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Peptide Synthesis CDMO Services by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Significant Companies of GMP Services
Table 15. Significant Companies of Non-GMP Services
Table 16. Global Peptide Synthesis CDMO Services Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 17. Global Peptide Synthesis CDMO Services Sales Value by Type (2021-2026) & (US$ Million)
Table 18. Global Peptide Synthesis CDMO Services Sales Value by Type (2027-2032) & (US$ Million)
Table 19. Global Peptide Synthesis CDMO Services Sales Value Share by Type (2021-2026)
Table 20. Global Peptide Synthesis CDMO Services Sales Value Share by Type (2027-2032)
Table 21. Significant Companies of Commercial
Table 22. Significant Companies of Scientific Research
Table 23. Significant Companies of Other
Table 24. Global Peptide Synthesis CDMO Services Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 25. Global Peptide Synthesis CDMO Services Sales Value by Application (2021-2026) & (US$ Million)
Table 26. Global Peptide Synthesis CDMO Services Sales Value by Application (2027-2032) & (US$ Million)
Table 27. Global Peptide Synthesis CDMO Services Sales Value Share by Application (2021-2026)
Table 28. Global Peptide Synthesis CDMO Services Sales Value Share by Application (2027-2032)
Table 29. Global Peptide Synthesis CDMO Services Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 30. Global Peptide Synthesis CDMO Services Sales Value by Region (2021-2026) & (US$ Million)
Table 31. Global Peptide Synthesis CDMO Services Sales Value Share by Region (2021-2026)
Table 32. Global Peptide Synthesis CDMO Services Sales Value by Region (2027-2032) & (US$ Million)
Table 33. Global Peptide Synthesis CDMO Services Sales Value Share by Region (2027-2032)
Table 34. Global Peptide Synthesis CDMO Services Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 35. Global Peptide Synthesis CDMO Services Sales Value by Country (2021-2026) & (US$ Million)
Table 36. Global Peptide Synthesis CDMO Services Sales Value Market Share by Country (2021-2026)
Table 37. Global Peptide Synthesis CDMO Services Sales Value by Country (2027-2032) & (US$ Million)
Table 38. Global Peptide Synthesis CDMO Services Sales Value Market Share by Country (2027-2032)
Table 39. Bachem Company Information
Table 40. Bachem Business Overview
Table 41. Bachem Peptide Synthesis CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 42. Bachem Peptide Synthesis CDMO Services Product Portfolio
Table 43. Bachem Recent Development
Table 44. CordenPharma Company Information
Table 45. CordenPharma Business Overview
Table 46. CordenPharma Peptide Synthesis CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 47. CordenPharma Peptide Synthesis CDMO Services Product Portfolio
Table 48. CordenPharma Recent Development
Table 49. PolyPeptide Company Information
Table 50. PolyPeptide Business Overview
Table 51. PolyPeptide Peptide Synthesis CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 52. PolyPeptide Peptide Synthesis CDMO Services Product Portfolio
Table 53. PolyPeptide Recent Development
Table 54. AmbioPharm Company Information
Table 55. AmbioPharm Business Overview
Table 56. AmbioPharm Peptide Synthesis CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 57. AmbioPharm Peptide Synthesis CDMO Services Product Portfolio
Table 58. AmbioPharm Recent Development
Table 59. Genscript Company Information
Table 60. Genscript Business Overview
Table 61. Genscript Peptide Synthesis CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Genscript Peptide Synthesis CDMO Services Product Portfolio
Table 63. Genscript Recent Development
Table 64. Thermo Fisher Company Information
Table 65. Thermo Fisher Business Overview
Table 66. Thermo Fisher Peptide Synthesis CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 67. Thermo Fisher Peptide Synthesis CDMO Services Product Portfolio
Table 68. Thermo Fisher Recent Development
Table 69. USV Peptides Company Information
Table 70. USV Peptides Business Overview
Table 71. USV Peptides Peptide Synthesis CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 72. USV Peptides Peptide Synthesis CDMO Services Product Portfolio
Table 73. USV Peptides Recent Development
Table 74. Bio Basic Company Information
Table 75. Bio Basic Business Overview
Table 76. Bio Basic Peptide Synthesis CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 77. Bio Basic Peptide Synthesis CDMO Services Product Portfolio
Table 78. Bio Basic Recent Development
Table 79. ScinoPharm Company Information
Table 80. ScinoPharm Business Overview
Table 81. ScinoPharm Peptide Synthesis CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 82. ScinoPharm Peptide Synthesis CDMO Services Product Portfolio
Table 83. ScinoPharm Recent Development
Table 84. JPT Company Information
Table 85. JPT Business Overview
Table 86. JPT Peptide Synthesis CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 87. JPT Peptide Synthesis CDMO Services Product Portfolio
Table 88. JPT Recent Development
Table 89. CBL Company Information
Table 90. CBL Business Overview
Table 91. CBL Peptide Synthesis CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 92. CBL Peptide Synthesis CDMO Services Product Portfolio
Table 93. CBL Recent Development
Table 94. Piramal Pharma Company Information
Table 95. Piramal Pharma Business Overview
Table 96. Piramal Pharma Peptide Synthesis CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 97. Piramal Pharma Peptide Synthesis CDMO Services Product Portfolio
Table 98. Piramal Pharma Recent Development
Table 99. CPC Scientific Company Information
Table 100. CPC Scientific Business Overview
Table 101. CPC Scientific Peptide Synthesis CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 102. CPC Scientific Peptide Synthesis CDMO Services Product Portfolio
Table 103. CPC Scientific Recent Development
Table 104. Creative Peptides Company Information
Table 105. Creative Peptides Business Overview
Table 106. Creative Peptides Peptide Synthesis CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 107. Creative Peptides Peptide Synthesis CDMO Services Product Portfolio
Table 108. Creative Peptides Recent Development
Table 109. Chinese Peptide Company Company Information
Table 110. Chinese Peptide Company Business Overview
Table 111. Chinese Peptide Company Peptide Synthesis CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 112. Chinese Peptide Company Peptide Synthesis CDMO Services Product Portfolio
Table 113. Chinese Peptide Company Recent Development
Table 114. ChengDu ShengNuo Biotec Company Information
Table 115. ChengDu ShengNuo Biotec Business Overview
Table 116. ChengDu ShengNuo Biotec Peptide Synthesis CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 117. ChengDu ShengNuo Biotec Peptide Synthesis CDMO Services Product Portfolio
Table 118. ChengDu ShengNuo Biotec Recent Development
Table 119. AppTec Co., Ltd. Company Information
Table 120. AppTec Co., Ltd. Business Overview
Table 121. AppTec Co., Ltd. Peptide Synthesis CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 122. AppTec Co., Ltd. Peptide Synthesis CDMO Services Product Portfolio
Table 123. AppTec Co., Ltd. Recent Development
Table 124. GL Biochem Company Information
Table 125. GL Biochem Business Overview
Table 126. GL Biochem Peptide Synthesis CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 127. GL Biochem Peptide Synthesis CDMO Services Product Portfolio
Table 128. GL Biochem Recent Development
Table 129. Research Programs/Design for This Report
Table 130. Authors List of This Report
Table 131. Secondary Sources
Table 132. Primary Sources
List of Figures
Figure 1. Peptide Synthesis CDMO Services Product Image
Figure 2. Global Peptide Synthesis CDMO Services Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Peptide Synthesis CDMO Services Market Size (2021-2032) & (US$ Million)
Figure 4. Global Peptide Synthesis CDMO Services Company Revenue Ranking in 2025 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 7. GMP Services Image
Figure 8. Non-GMP Services Image
Figure 9. Global Peptide Synthesis CDMO Services Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 10. Global Peptide Synthesis CDMO Services Sales Value Share 2021 VS 2025 VS 2032
Figure 11. Global Peptide Synthesis CDMO Services Sales Value Share by Type (2021-2032)
Figure 12. Commercial Image
Figure 13. Scientific Research Image
Figure 14. Other Image
Figure 15. Global Peptide Synthesis CDMO Services Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 16. Global Peptide Synthesis CDMO Services Sales Value Share 2021 VS 2025 VS 2032
Figure 17. Global Peptide Synthesis CDMO Services Sales Value Share by Application (2021-2032)
Figure 18. Global Peptide Synthesis CDMO Services Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 19. Global Peptide Synthesis CDMO Services Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 20. North America Peptide Synthesis CDMO Services Sales Value (2021-2032) & (US$ Million)
Figure 21. North America Peptide Synthesis CDMO Services Sales Value Share by Country (%), 2025 VS 2032
Figure 22. Europe Peptide Synthesis CDMO Services Sales Value (2021-2032) & (US$ Million)
Figure 23. Europe Peptide Synthesis CDMO Services Sales Value Share by Country (%), 2025 VS 2032
Figure 24. Asia-Pacific Peptide Synthesis CDMO Services Sales Value (2021-2032) & (US$ Million)
Figure 25. Asia-Pacific Peptide Synthesis CDMO Services Sales Value Share by Country (%), 2025 VS 2032
Figure 26. South America Peptide Synthesis CDMO Services Sales Value (2021-2032) & (US$ Million)
Figure 27. South America Peptide Synthesis CDMO Services Sales Value Share by Country (%), 2025 VS 2032
Figure 28. Middle East & Africa Peptide Synthesis CDMO Services Sales Value (2021-2032) & (US$ Million)
Figure 29. Middle East & Africa Peptide Synthesis CDMO Services Sales Value Share by Country (%), 2025 VS 2032
Figure 30. USA Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 31. USA Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 32. USA Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 33. Canada Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 34. Canada Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 35. Canada Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 36. Mexico Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 37. Mexico Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 38. Mexico Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 39. Germany Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 40. Germany Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 41. Germany Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 42. France Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 43. France Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 44. France Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 45. U.K. Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 46. U.K. Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 47. U.K. Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 48. Italy Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 49. Italy Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 50. Italy Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 51. Spain Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 52. Spain Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 53. Spain Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 54. Russia Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 55. Russia Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 56. Russia Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 57. Netherlands Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 58. Netherlands Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 59. Netherlands Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 60. Nordic Countries Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 61. Nordic Countries Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 62. Nordic Countries Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 63. China Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 64. China Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 65. China Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 66. Japan Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 67. Japan Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 68. Japan Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 69. South Korea Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 70. South Korea Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 71. South Korea Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 72. India Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 73. India Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 74. India Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 75. Australia Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 76. Australia Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 77. Australia Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 78. Southeast Asia Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 79. Southeast Asia Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 80. Southeast Asia Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 81. Brazil Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 82. Brazil Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 83. Brazil Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 84. Argentina Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 85. Argentina Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 86. Argentina Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 87. Chile Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 88. Chile Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 89. Chile Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 90. Colombia Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 91. Colombia Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 92. Colombia Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 93. Peru Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 94. Peru Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 95. Peru Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 96. Saudi Arabia Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 97. Saudi Arabia Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 98. Saudi Arabia Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 99. Israel Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 100. Israel Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 101. Israel Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 102. UAE Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 103. UAE Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 104. UAE Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 105. Turkey Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 106. Turkey Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 107. Turkey Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 108. Iran Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 109. Iran Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 110. Iran Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 111. Egypt Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 112. Egypt Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 113. Egypt Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 114. Years Considered
Figure 115. Research Process
Figure 116. Key Executives Interviewed
Scope & coverage.
Types
- GMP Services
- Non-GMP Services
Applications
- Commercial
- Scientific Research
- Other
Companies covered
- Bachem
- CordenPharma
- PolyPeptide
- AmbioPharm
- Genscript
- Thermo Fisher
- USV Peptides
- Bio Basic
- ScinoPharm
- JPT
- CBL
- Piramal Pharma
- CPC Scientific
- Creative Peptides
- Chinese Peptide Company
- ChengDu ShengNuo Biotec
- AppTec Co., Ltd.
- GL Biochem
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Peptide Synthesis CDMO Services Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Peptide Synthesis CDMO Services Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Peptide Synthesis CDMO Services Market Dynamics
- 2.1 Peptide Synthesis CDMO Services Industry Trends
- 2.2 Peptide Synthesis CDMO Services Industry Drivers
- 2.3 Peptide Synthesis CDMO Services Industry Opportunities and Challenges
- 2.4 Peptide Synthesis CDMO Services Industry Restraints
3 Peptide Synthesis CDMO Services Market by Company
- 3.1 Global Peptide Synthesis CDMO Services Company Revenue Ranking in 2025
- 3.2 Global Peptide Synthesis CDMO Services Revenue by Company (2021-2026)
- 3.3 Global Peptide Synthesis CDMO Services Company Ranking (2024-2026)
- 3.4 Global Peptide Synthesis CDMO Services Company Manufacturing Base and Headquarters
- 3.5 Global Peptide Synthesis CDMO Services Company Product Type and Application
- 3.6 Global Peptide Synthesis CDMO Services Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Peptide Synthesis CDMO Services Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Peptide Synthesis CDMO Services Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Peptide Synthesis CDMO Services Market by Type
- 4.1 Peptide Synthesis CDMO Services Type Introduction
- 4.1.1 GMP Services
- 4.1.2 Non-GMP Services
- 4.2 Global Peptide Synthesis CDMO Services Sales Value by Type
- 4.2.1 Global Peptide Synthesis CDMO Services Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Peptide Synthesis CDMO Services Sales Value by Type (2021-2032)
- 4.2.3 Global Peptide Synthesis CDMO Services Sales Value Share by Type (2021-2032)
5 Peptide Synthesis CDMO Services Market by Application
- 5.1 Peptide Synthesis CDMO Services Application Introduction
- 5.1.1 Commercial
- 5.1.2 Scientific Research
- 5.1.3 Other
- 5.2 Global Peptide Synthesis CDMO Services Sales Value by Application
- 5.2.1 Global Peptide Synthesis CDMO Services Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Peptide Synthesis CDMO Services Sales Value by Application (2021-2032)
- 5.2.3 Global Peptide Synthesis CDMO Services Sales Value Share by Application (2021-2032)
6 Peptide Synthesis CDMO Services Regional Value Analysis
- 6.1 Global Peptide Synthesis CDMO Services Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Peptide Synthesis CDMO Services Sales Value by Region (2021-2032)
- 6.2.1 Global Peptide Synthesis CDMO Services Sales Value by Region: 2021-2026
- 6.2.2 Global Peptide Synthesis CDMO Services Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Peptide Synthesis CDMO Services Sales Value (2021-2032)
- 6.3.2 North America Peptide Synthesis CDMO Services Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Peptide Synthesis CDMO Services Sales Value (2021-2032)
- 6.4.2 Europe Peptide Synthesis CDMO Services Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Peptide Synthesis CDMO Services Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Peptide Synthesis CDMO Services Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Peptide Synthesis CDMO Services Sales Value (2021-2032)
- 6.6.2 South America Peptide Synthesis CDMO Services Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Peptide Synthesis CDMO Services Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Peptide Synthesis CDMO Services Sales Value Share by Country, 2025 VS 2032
7 Peptide Synthesis CDMO Services Country-level Value Analysis
- 7.1 Global Peptide Synthesis CDMO Services Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Peptide Synthesis CDMO Services Sales Value by Country (2021-2032)
- 7.2.1 Global Peptide Synthesis CDMO Services Sales Value by Country (2021-2026)
- 7.2.2 Global Peptide Synthesis CDMO Services Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.7.2 France Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.14.2 China Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.17.2 India Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Peptide Synthesis CDMO Services Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Peptide Synthesis CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Peptide Synthesis CDMO Services Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Bachem
- 8.1.1 Bachem Company Information
- 8.1.2 Bachem Business Overview
- 8.1.3 Bachem Peptide Synthesis CDMO Services Revenue and Gross Margin (2021-2026)
- 8.1.4 Bachem Peptide Synthesis CDMO Services Product Portfolio
- 8.1.5 Bachem Recent Developments
- 8.2 CordenPharma
- 8.2.1 CordenPharma Company Information
- 8.2.2 CordenPharma Business Overview
- 8.2.3 CordenPharma Peptide Synthesis CDMO Services Revenue and Gross Margin (2021-2026)
- 8.2.4 CordenPharma Peptide Synthesis CDMO Services Product Portfolio
- 8.2.5 CordenPharma Recent Developments
- 8.3 PolyPeptide
- 8.3.1 PolyPeptide Company Information
- 8.3.2 PolyPeptide Business Overview
- 8.3.3 PolyPeptide Peptide Synthesis CDMO Services Revenue and Gross Margin (2021-2026)
- 8.3.4 PolyPeptide Peptide Synthesis CDMO Services Product Portfolio
- 8.3.5 PolyPeptide Recent Developments
- 8.4 AmbioPharm
- 8.4.1 AmbioPharm Company Information
- 8.4.2 AmbioPharm Business Overview
- 8.4.3 AmbioPharm Peptide Synthesis CDMO Services Revenue and Gross Margin (2021-2026)
- 8.4.4 AmbioPharm Peptide Synthesis CDMO Services Product Portfolio
- 8.4.5 AmbioPharm Recent Developments
- 8.5 Genscript
- 8.5.1 Genscript Company Information
- 8.5.2 Genscript Business Overview
- 8.5.3 Genscript Peptide Synthesis CDMO Services Revenue and Gross Margin (2021-2026)
- 8.5.4 Genscript Peptide Synthesis CDMO Services Product Portfolio
- 8.5.5 Genscript Recent Developments
- 8.6 Thermo Fisher
- 8.6.1 Thermo Fisher Company Information
- 8.6.2 Thermo Fisher Business Overview
- 8.6.3 Thermo Fisher Peptide Synthesis CDMO Services Revenue and Gross Margin (2021-2026)
- 8.6.4 Thermo Fisher Peptide Synthesis CDMO Services Product Portfolio
- 8.6.5 Thermo Fisher Recent Developments
- 8.7 USV Peptides
- 8.7.1 USV Peptides Company Information
- 8.7.2 USV Peptides Business Overview
- 8.7.3 USV Peptides Peptide Synthesis CDMO Services Revenue and Gross Margin (2021-2026)
- 8.7.4 USV Peptides Peptide Synthesis CDMO Services Product Portfolio
- 8.7.5 USV Peptides Recent Developments
- 8.8 Bio Basic
- 8.8.1 Bio Basic Company Information
- 8.8.2 Bio Basic Business Overview
- 8.8.3 Bio Basic Peptide Synthesis CDMO Services Revenue and Gross Margin (2021-2026)
- 8.8.4 Bio Basic Peptide Synthesis CDMO Services Product Portfolio
- 8.8.5 Bio Basic Recent Developments
- 8.9 ScinoPharm
- 8.9.1 ScinoPharm Company Information
- 8.9.2 ScinoPharm Business Overview
- 8.9.3 ScinoPharm Peptide Synthesis CDMO Services Revenue and Gross Margin (2021-2026)
- 8.9.4 ScinoPharm Peptide Synthesis CDMO Services Product Portfolio
- 8.9.5 ScinoPharm Recent Developments
- 8.10 JPT
- 8.10.1 JPT Company Information
- 8.10.2 JPT Business Overview
- 8.10.3 JPT Peptide Synthesis CDMO Services Revenue and Gross Margin (2021-2026)
- 8.10.4 JPT Peptide Synthesis CDMO Services Product Portfolio
- 8.10.5 JPT Recent Developments
- 8.11 CBL
- 8.11.1 CBL Company Information
- 8.11.2 CBL Business Overview
- 8.11.3 CBL Peptide Synthesis CDMO Services Revenue and Gross Margin (2021-2026)
- 8.11.4 CBL Peptide Synthesis CDMO Services Product Portfolio
- 8.11.5 CBL Recent Developments
- 8.12 Piramal Pharma
- 8.12.1 Piramal Pharma Company Information
- 8.12.2 Piramal Pharma Business Overview
- 8.12.3 Piramal Pharma Peptide Synthesis CDMO Services Revenue and Gross Margin (2021-2026)
- 8.12.4 Piramal Pharma Peptide Synthesis CDMO Services Product Portfolio
- 8.12.5 Piramal Pharma Recent Developments
- 8.13 CPC Scientific
- 8.13.1 CPC Scientific Company Information
- 8.13.2 CPC Scientific Business Overview
- 8.13.3 CPC Scientific Peptide Synthesis CDMO Services Revenue and Gross Margin (2021-2026)
- 8.13.4 CPC Scientific Peptide Synthesis CDMO Services Product Portfolio
- 8.13.5 CPC Scientific Recent Developments
- 8.14 Creative Peptides
- 8.14.1 Creative Peptides Company Information
- 8.14.2 Creative Peptides Business Overview
- 8.14.3 Creative Peptides Peptide Synthesis CDMO Services Revenue and Gross Margin (2021-2026)
- 8.14.4 Creative Peptides Peptide Synthesis CDMO Services Product Portfolio
- 8.14.5 Creative Peptides Recent Developments
- 8.15 Chinese Peptide Company
- 8.15.1 Chinese Peptide Company Company Information
- 8.15.2 Chinese Peptide Company Business Overview
- 8.15.3 Chinese Peptide Company Peptide Synthesis CDMO Services Revenue and Gross Margin (2021-2026)
- 8.15.4 Chinese Peptide Company Peptide Synthesis CDMO Services Product Portfolio
- 8.15.5 Chinese Peptide Company Recent Developments
- 8.16 ChengDu ShengNuo Biotec
- 8.16.1 ChengDu ShengNuo Biotec Company Information
- 8.16.2 ChengDu ShengNuo Biotec Business Overview
- 8.16.3 ChengDu ShengNuo Biotec Peptide Synthesis CDMO Services Revenue and Gross Margin (2021-2026)
- 8.16.4 ChengDu ShengNuo Biotec Peptide Synthesis CDMO Services Product Portfolio
- 8.16.5 ChengDu ShengNuo Biotec Recent Developments
- 8.17 AppTec Co., Ltd.
- 8.17.1 AppTec Co., Ltd. Company Information
- 8.17.2 AppTec Co., Ltd. Business Overview
- 8.17.3 AppTec Co., Ltd. Peptide Synthesis CDMO Services Revenue and Gross Margin (2021-2026)
- 8.17.4 AppTec Co., Ltd. Peptide Synthesis CDMO Services Product Portfolio
- 8.17.5 AppTec Co., Ltd. Recent Developments
- 8.18 GL Biochem
- 8.18.1 GL Biochem Company Information
- 8.18.2 GL Biochem Business Overview
- 8.18.3 GL Biochem Peptide Synthesis CDMO Services Revenue and Gross Margin (2021-2026)
- 8.18.4 GL Biochem Peptide Synthesis CDMO Services Product Portfolio
- 8.18.5 GL Biochem Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst